Intake Breathing sells $40 nasal strips as status signaling after PE firm invests $62 million in breathing optimization

Intake Breathing took in $62 million from private equity firm Camino Partners to position nasal strips—the same category CVS sells for $8—as a status symbol for optimized performance, according to Glossy. The brand's CEO Alex Huack and Camino president Elle Lanning told the outlet they're betting high-net-worth buyers will pay a premium for breathing gear that signals membership in a quantified wellness class.

The product itself is a nasal dilator strip. The move is positioning: Intake wrapped the strip in clinical language about airflow optimization, partnered with elite athletes as validators, and priced it at the luxury end of the category. The brand claims each strip improves nasal airflow by up to 50%, cited in the Glossy interview, and packages that benefit not as a medical fix but as a performance edge accessible only to those who know.

This works because status goods require three elements: functional differentiation that's hard to verify, aesthetic codes that separate insiders from mass buyers, and scarcity—real or perceived. Intake delivers all three. The airflow claim is real but not meaningfully different from cheaper competitors; the verification requires tools most consumers don't own. The brand's monochrome packaging and premium retail placement at Erewhon signal high cost and curation. And the $62 million PE backing itself becomes part of the story: someone credible bet big, so this must be the insider choice.

Camino Partners chose Intake specifically to build what Lanning called a breathing optimization platform, per Glossy. The strategy is to anchor the category around a single brand before competitors can claim the language. Private equity backing accelerates that land-grab: it funds retail placement, influencer seeding, and the kind of earned media that makes a niche product feel inevitable. The firm is treating breathing the way earlier wellness investors treated adaptogens or electrolytes—find the science-adjacent claim, wrap it in aspiration, scale before the window closes.

A small physical-product brand can steal this without PE capital. The play is to take a commodity item your customer already buys and reposition it as a tool for a specific, aspirational identity. Find the functional claim that's true but underexploited—airflow, hydration, focus, recovery. Write that claim in clinical language but sell it as insider knowledge. Then change every aesthetic signal: packaging, price, the retail or digital environment where it appears, and the people who visibly use it. A $12 product becomes a $35 product when it's the thing people in your target circle recognize as the serious choice.

Execution: Identify your commodity equivalent and the measurable benefit it delivers. Rewrite your landing page and product copy to sound like research findings, not marketing. Swap your packaging for something that looks like it came from a medical supply company or a members-only club—minimal color, technical typography, no lifestyle photography. Price at 2-3x the commodity, not 10x, so the customer feels smart but still elevated. Seed it to 3-5 people whose recommendations your audience monitors, and let them explain why they switched. The status comes from the shift itself, not the size of the ad buy.

The pattern here is that wellness products compete on signals, not efficacy. Intake's $62 million round won't change how nasal strips work; it will change who feels comfortable buying them and what that purchase says about the buyer. That's the repeatable move for any founder selling a physical good in a category where the functional difference is narrow but the identity difference is wide.